Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.
Keir HR, Long MB, Abo-Leyah H, Giam YH, Vadiveloo T, Pembridge T, Hull RC, Delgado L, Band M, McLaren-Neil F, Adamson S, Lahnsteiner E, Gilmour A, Hughes C, New BJ, Connell D, Dowey R, Turton H, Richardson H, Cassidy D, Cooper J, Suntharalingam J, Diwakar L, Russell P, Underwood J, Hicks A, Dosanjh DP, Sage B, Dhasmana D, Spears M, Thompson AR, Brightling C, Smith A, Patel M, George J, Condliffe AM, Shoemark A, MacLennan G, Chalmers JD; STOP-COVID19 Investigators.
Keir HR, et al. Among authors: dhasmana d.
Lancet Respir Med. 2022 Dec;10(12):1119-1128. doi: 10.1016/S2213-2600(22)00261-2. Epub 2022 Sep 5.
Lancet Respir Med. 2022.
PMID: 36075243
Free PMC article.
Clinical Trial.